Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?83
Mesothelin-targeted CAR-T cell therapy for solid tumors72
Core decompression isolated or combined with bone marrow-derived cell therapies for femoral head osteonecrosis54
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology48
Therapeutic monoclonal antibodies for COVID-19 management: an update45
New frontiers in personalized medicine in psoriasis44
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma43
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study40
Targeting the complement system in neuromyelitis optica spectrum disorder40
Treating psoriasis in the elderly: biologics and small molecules34
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions33
A comprehensive review on sarilumab in COVID-1932
Anti-CD20 treatment for B-cell malignancies: current status and future directions31
Hemophilia A gene therapy: current and next-generation approaches30
What makes a good antibody–drug conjugate?29
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan29
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics29
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis28
Immune checkpoint inhibition in COVID-19: risks and benefits27
The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database27
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy27
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?26
Margetuximab for the treatment of HER2-positive metastatic breast cancer26
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?25
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-1925
Anticalin® proteins: from bench to bedside25
0.040359973907471